Colorectal

Sedation Method Does Not Affect Colonoscopy Detection Rate

(University of Missouri) June 18, 2019 - Researchers from the University of Missouri School of Medicine determined deep sedation does not improve the colonoscopy quality compared to moderate sedation when it comes to the polyp detection rate or adenoma detection rate, the type of polyp that can eventually become cancerous.

read article

Improved Treatment Options For Colorectal Cancer Could Be On The Horizon

(Keck/USC) June 12, 2019 - Researchers at the USC Norris Comprehensive Cancer Center found that identifying a metastatic colorectal cancer patient’s Consensus Molecular Subtype (CMS) could help oncologists determine the most effective course of treatment.

read article

Some Colorectal Cancers Are "Born To Be Bad," Have Already Spread Long Before Diagnosis

(Forbes) June 17, 2019 - Four out of five metastatic colorectal cancers have already spread before they are even diagnosed, according to new research out today, led by researchers at Stanford University.

read article

A Gut Feeling: Microbiome Changes May Mean Early Detection Of Colorectal Cancer

(Osaka University [Japan]) June 7, 2019 - A group of researchers from Osaka University have recently reported increases in specific microbiome organisms that are linked to the malignancies associated with colorectal cancer, such as intramucosal carcinomas and polypoid adenomas.

read article

First Patient Dosed with Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer, and Renal Cell Carcinoma

(NASDAQ) June 13, 2019 - XOMA Corporation announced today that gevokizumab, an anti-IL1β monoclonal antibody that XOMA discovered and initially developed, is now actively progressing in a Novartis oncology development program.

read article

Next Up For KRAS-Blocking Cancer Drug Fans: A Hugely Important Data Reveal From Mirati Therapeutics

(STAT Plus) June 12, 2019 - After the impressive tumor-shrinking data shown by Amgen from its KRAS-targeted cancer drug at the recently completed ASCO meeting, attention — and pressure — now shift to Mirati Therapeutics and its competing KRAS blocker.

read article (paid subscription required)

The Elderly Are Getting Complex Surgeries. Often It Doesn’t End Well.

(New York Times) June 7, 2019 - Complication rates are high among the oldest patients. Now a surgeons’ group will propose standards for hospitals operating on the elderly. People over 65 represent roughly 16 percent of the American population, but account for 40 percent of patients undergoing surgery in hospitals — and probably more than half of all surgical procedures.

read article

Vitamin D and Colorectal Cancer Survival

(Yale Medicine) June 10, 2019 - The results of the vitamin D ‘Sunshine Trial’ are in.

read article

Actress Shines Light On HPV’s Link To Anal Cancer

(CNN) June 7, 2019 - Actress Marcia Cross has been public about her anal cancer diagnosis for more than a year. Now she says doctors suspect her cancer came from the same type of human papillomavirus, or HPV, that's behind her husband's throat cancer.

read article

Boston Biomedical, Inc. Announces the Continuation of the Phase 3 CanStem303C Study of Napabucasin in Patients with Advanced Colorectal Cancer Following Interim Analysis

(Markets Insider) June 6, 2019 - Boston Biomedical, Inc. today announced the continuation of the CanStem303C study evaluating the safety and efficacy of investigational agent napabucasin when given in combination with FOLFIRI with or without bevacizumab in patients with advanced colorectal cancer.

read article

Colorectal Cancer Patients With Liver Metastases Live Just as Long After Laparoscopic Surgery as Open Surgery

(2019 ASCO) June 3, 2019 - The randomized OSLO-COMET trial found that laparoscopic surgery did not change chances of survival, when compared to open surgery, to remove metastases that had spread to the liver in patients with colorectal cancer. Overall, patients lived more than 6.5 years after surgery, regardless of whether it was laparoscopic or open. The study will be featured in a press briefing today and presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

read press release

Survival After Laparoscopy Similar to Open Surgery

(MedPage Today) June 3, 2019 - Minimally-invasive laparoscopic surgery successfully eliminated colorectal metastases in the liver, providing the same long-term survival and disease-free recurrence risk as open surgery, researchers reported here. After 5 years, 57% of the 147 patients undergoing open surgery in the intention-to-treat population were still alive compared with 56% of the 133 patients who were treated with laparoscopy (P=0.91), reported Asmund Fretland, MD, of Oslo University Hospital in Norway, at a press conference at the American Society of Clinical Oncology's annual meeting.

read article (free registration required)

Taiho Oncology and Servier Present LONSURF® (trifluridine and tipiracil) Data at the 2019 ASCO Annual Meeting

(Taiho Oncology) June 3, 2019 - Taiho Oncology, Inc. and Servier announced today clinical data with LONSURF® (trifluridine and tipiracil, TAS-102) in previously treated patients with metastatic gastric cancer (mGC), metastatic gastroesophageal junction adenocarcinoma (mGEJC) and metastatic colorectal cancer (mCRC) were presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.

read corporate press release

Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019

(Amgen) June 3, 2019 - Amgen today announced the first clinical results from a Phase 1 study evaluating investigational AMG 510, the first KRASG12C inhibitor to reach the clinical stage.

read corporate press release

Here's Why Mirati Therapeutics Is Jumping Today

(Yahoo! Finance/The Motley Fool) June 3, 2019 - Shares of Mirati Therapeutics, a clinical-stage biopharmaceutical company with an oncology focus, are on the rise following a presentation from Amgen.

read article

Initial Experimental Treatment Arm Results from NRG Oncology Trial Suggests Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer is Safe

(NRG Oncology) June 1, 2019 - Results from the first experimental arm using veliparib as part of total neoadjuvant therapy (induction chemotherapy followed by chemoradiotherapy and surgery; TNT) in patients with locally advanced rectal adenocarcinoma on the NRG Oncology Phase II clinical trial NRG-GI002 were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

read press release

ASCO 2019: Drug Targeting DNA Damage Response Shows Promise Against Cancers Of Anus And Genitals

(ICR [UK]) June 1, 2019 - A precision medicine targeting a key protein which helps cancer cells to tolerate DNA damage has shown promising results in two clinical trials.

read article

Treating and Identifying the Factors Associated With Development of Bone Metastases

(AJMC Managed Markets Network) June 1, 2019 - Two abstracts at the 2019 American Society of Clinical Oncology Annual Meeting analyzed bone metastases in cancer. The first looked at treatment of bone metastases in various cancer, whereas the other identified factors associated with the development of bone metastases in patients with colorectal cancer.

read article

Small-Cap Biotechs Aim to Steal Spotlight at Cancer Meeting

(Bloomberg) May 31, 2019 - While Merck & Co. and Roche Holding AG have taken center stage at past conferences, the focus at this year’s American Society of Clinical Oncology meeting will be on more volatile small-cap drugmakers trying to advance new cancer treatments.

read article (free registration required)

Early Onset Colorectal Cancer Rising Fastest in the West

(American Cancer Society) May 29, 2019 - Early-onset colorectal cancer—cancer occurring before age 50—is rising most rapidly in Western states, where healthy behaviors are prominent, according to a new study. The authors of the study, which appears in the Journal of the National Cancer Institute, say the findings indicate the need for further etiologic studies to explore early-life colorectal carcinogenesis. Early-onset colorectal cancer (CRC) has been on the rise for several decades in the United States for unknown reasons. Because geographic differences could help uncover potential causes for the trend, investigators at the American Cancer Society and The Ohio State University analyzed changes in CRC incidence and risk factors among adults under 50 during 1995-2015 by state and race/ethnicity.

read press release
Next Page